In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications

Jayash SN 1 , Hashim NM 2 , Misran M 3 , Baharuddin NA 1

Affiliations 

  • 1 Department of Restorative Dentistry, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Department of Pharmacy, Faculty of Medicine, University of Malaya,Kuala Lumpur,Malaysia; Centre For Natural Products And Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya,Kuala Lumpur,Malaysia
  • 3 Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
PeerJ, 2016;4:e2229.
PMID: 27635307 DOI: 10.7717/peerj.2229

Abstract

The receptor activator of nuclear factor kappa-B (RANK)/RANK ligand/osteoprotegerin (OPG) system plays a critical role in bone remodelling by regulating osteoclast formation and activity. OPG has been used systemically in the treatment of bone diseases. In searching for more effective and safer treatment for bone diseases, we investigated newly formulated OPG-chitosan complexes, which is prepared as a local application for its osteogenic potential to remediate bone defects.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications